弥漫大B细胞淋巴瘤患者化疗前后淋巴细胞亚群动态变化及其意义

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (0 KB) HTML (50 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the changes of lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+)in peripheral blood before and after chemotherapy in patients with diffuse large B-cell lymphoma(DLBCL)and their clinical significance.Methods A total of 56 patients with DLBCL who visited Provincial Hospital affiliated to Anhui Medical University for the first time from May 2018 to May 2020 were retrospectively selected as the research subjects,and all patients were pathologically confirmed.According to the ratio of CD4+/CD8+in peripheral blood before chemotherapy,the patients were divided into two groups as the elevated/normal group(group A)39 cases and the reduced group(group B)17 cases.All patients received R-CHOP regimen after admission,After four cycles of chemotherapy,the patients were divided into elevated/normal group(group C)31 cases and decreased group(group D)25 cases according to the ratio of CD4+/CD8+in peripheral blood,and analyzed the changes of immune function and its relationship with prognosis in patients with different clinical characteristics.Results After treatment,the levels of CD3+and CD8+in two groups were higher than before treatment,while the level of CD4+/CD8+was lower than before treatment,the differences were statistically significant(P＜0.05).After treatment,the patients in group A had less progression than group B,and the progression-free survival time in group A was longer than that in group B,the differences were statistically significant(P＜0.05).The incidence of thrombocytopenia in group D was higher than that in group C,and the difference was statistically significant(P＜0.05).Conclusion The immunestatus of patients with diffuse large B-cell lymphoma have changed,and the detection of peripheral blood lymphocyte subsets was of high value for the evaluation and diagnosis.Peripheral blood immune cell monitoring of patients could timely determine the immune status of patients in order to better guide the use of chemotherapy drugs.

Key words： Lymphoma Immunotherapy Immunologic function Lymphocyte subsets

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YU Lu
	DING Kai-yang

Cite this article:

YU Lu,DING Kai-yang. Dynamic changes of lymphocyte subsets in patients with diffuse large Bcell lymphoma before and after chemotherapy and its significance[J]. 中国当代医药, 2021, 28(14): 13-17.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I14/13

[1]	Li S，Young KH，Medeiros LJ.Diffuse large B-cell lymphoma[J].Pathology，2018，50（1）：74-87.
[2]	李丽燕，付蓉.复发难治性弥漫大B细胞淋巴瘤靶向药物治疗进展[J].中国肿瘤临床，2019，46（11）：581-585.
[3]	甄敬飞，包芳，朱明霞，等.外周血免疫细胞亚群的变化与B细胞淋巴瘤患者的预后关系研究[J].中国实验血液学杂志，2018，26（6）：1657-1662.
[4]	李军民，管忠震，沈悌，等.中国弥漫大B细胞淋巴瘤诊断与治疗指南（2013年版）[J].中华血液学杂志，2013，34（9）：816-819.
[5]	Oken MM，Creech RH，Tormey DC，et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group[J].Am J Clin Oncol，1982，5（6）：649-655.
[6]	Skrabek P，Assouline S，Christofides A，et al.Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma[J].Curr Oncol，2019，26（4）：253-265.
[7]	Rosenthal A，Younes A.High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6：Double hit and triple hit lymphomas and double expressing lymphoma[J].Blood Rev，2017，31（2）：37-42.
[8]	Mondello P，Mian M.Frontline treatment of diffuse large Bcell lymphoma：Beyond R-CHOP[J].Hematol Oncol，2019，37（4）：333-344.
[9]	肖蓉，姜涛，万纯黔，等.弥漫大B细胞淋巴瘤治疗后血清β2-MGVEGF与LDH水平变化及其临床意义[J].中国肿瘤临床，2018，45（19）：994-999.
[10]	Batlevi CL，Matsuki E，Brentjens RJ，et al.Novel immunotherapies in lymphoid malignancies[J].Nat Rev Clin Oncol，2016，13（1）：25-40.
[11]	徐慧雯，陈波斌.布鲁顿酪氨酸激酶抑制剂治疗B细胞肿瘤的研究进展[J].上海医药，2019，40（11）：3-7.
[12]	Nowakowski GS，LaPlant B，Macon WR，et al.Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma：a phaseⅡstudy[J].J Clin Oncol，2015，33（3）：251-257.
[13]	Van Den Neste E，Schmitz N，Mounier N，et al.Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation：an analysis of patients included in the CORAL study[J].Bone Marrow Transplant，2017，52（2）：216-221.
[14]	Hopfinger G，Jer U，Worel N.CAR-T cell therapy in diffuse large B cell lymphoma:hype and hope[J].Hemasphere，2019，3（2）：e185.
[15]	Sun LL，Ellerman D，Mathieu M，et al.Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies[J].Sci Transl Med，2015，7（287）：287ra70.
[16]	杨德芬.外周血T细胞亚群检测在恶性肿瘤中的应用及临床意义[J].海南医学院学报，2013，19（10）：1390-1392，1395.
[17]	Chen T，Chen Y，Bao W，et al.T-lymphocyte subsets and Th1/Th2 cytokines in convalescent patients with Epstein-Barr virus-associated aplastic anemia[J].Hematology，2020，25（1）：11-16.
[18]	冯晓丽.外周血T细胞亚群检测在恶性肿瘤中的价值[J].临床研究，2018，26（5）：137-138.
[19]	葛华，杨新蔚，袁帆.非霍奇金淋巴瘤患者化疗前后T淋巴细胞亚群变化及临床意义[J].内科，2016，11（3）：398-400.
[20]	冉隆荣，薛宁，王建容，等.恶性血液病患者外周血淋巴细胞亚群变化及其临床意义的研究[J].中国生物工程杂志，2019，39（9）：50-57.
[21]	陈派强.外周血T细胞亚群检测在恶性肿瘤中的价值[J].医药论坛杂志，2012，33（4）：118-119.
[22]	张司琪，葛健，夏瑞祥.急性白血病患者外周血T细胞亚群、NK细胞和调节性T细胞的检测及临床意义[J].安徽医科大学学报，2016，51（2）：218-221.
[23]	Heemskerk JW，Mattheij NJ，Cosemans JM.Platelet-based coagulation：different populations，different functions[J].J Thromb Haemost，2013，11（1）：2-16.